Stocks Health care LONA
NASDAQ · Health careLeonaBio, Inc. (LONA)
It posted a net loss of $141.5M. At June 30, 2026 it held $32.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about LeonaBio, Inc.
- Net worth
- LeonaBio, Inc. has a market value (market cap) of $37.9M at the latest share price, and shareholders' equity of $33.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $45.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- LeonaBio, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What LeonaBio, Inc. does
LeonaBio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker LONA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$105.6M | -$24.70 | n/a |
| 2024 | n/a | -$96.9M | -$25.19 | -$97.2M |
| 2023 | n/a | -$117.7M | -$30.89 | -$101.1M |
| 2022 | n/a | -$95.6M | -$25.29 | -$73.6M |
| 2021 | n/a | -$54.9M | -$14.89 | -$44.7M |
| 2020 | n/a | -$20M | -$16.69 | -$26.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What LeonaBio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026Other event 8-K
- August 31, 2026Activist stake (5% or more) SCHEDULE 13D
- August 26, 2026Other event 8-K
- August 25, 2026Activist stake changed SCHEDULE 13D/A
- August 20, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 14, 2026
- June 23, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 11, 2026
Insider trades
What the people running LeonaBio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 4, 2026 | Litton Mark JamesPRESIDENT and CEO, Director | Sold | 5,156 | $27.7K |
| March 4, 2026 | San Martin JavierCHIEF MEDICAL OFFICER | Sold | 1,720 | $9.2K |
| March 4, 2026 | Church KevinCHIEF SCIENTIFIC OFFICER | Sold | 1,359 | $7.3K |
| March 4, 2026 | Worthington MarkGENERAL COUNSEL and CCO | Sold | 1,328 | $7.1K |
| March 4, 2026 | Renninger RobertCHIEF FINANCIAL OFFICER | Sold | 906 | $4.9K |
| March 3, 2026 | Litton Mark JamesPRESIDENT and CEO, Director | Exercised options | 22,254 | - |
| March 3, 2026 | San Martin JavierCHIEF MEDICAL OFFICER | Exercised options | 7,418 | - |
| March 3, 2026 | Church KevinCHIEF SCIENTIFIC OFFICER | Exercised options | 5,856 | - |
Who owns LONA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Sermonix Pharmaceuticals, Inc.13D, may seek influence with 1 related filers | 36.9% | August 31, 2026 |
| Perceptive Advisors LLC13D, may seek influence with 3 related filers | 19.99% | August 25, 2026 |
| Anders Hove13G, passive with 4 related filers | 12.1% | August 20, 2026 |
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 7.7% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 44 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Perceptive Advisors LLC | 1,859,322 | 0 |
| Kalehua Capital Management LLC | 787,402 | 0 |
| ADAR1 Capital Management, LLC | 777,100 | +49,619 |
| Acorn Capital Advisors, LLC | 634,539 | 0 |
| NEA Management Company, LLC | 464,398 | 0 |
| Commodore Capital LP | 464,398 | 0 |
| TCG Crossover Management, LLC | 464,398 | 0 |
| Spruce Street Capital LP | 393,701 | 0 |
| Blackstone Inc. | 324,638 | new |
| Adage Capital Partners GP, L.L.C. | 300,000 | new |
| Vanguard Capital Management LLC | 275,233 | +80,473 |
| Seven Fleet Capital Management LP | 154,153 | -10,523 |
| Simplify Asset Management Inc. | 149,279 | 0 |
| Propel Bio Management, LLC | 149,279 | 0 |
| Geode Capital Management, LLC | 80,418 | +95 |
| BlackRock, Inc. | 79,186 | +23,135 |
| Renaissance Technologies LLC | 77,424 | +13,202 |
| Vanguard Fiduciary Trust Co | 42,814 | +2,775 |
| Bank of America Corp | 32,557 | -9 |
| Millennium Management LLC | 32,450 | +772 |
Insiders
6 insiders reported holding 462,974 shares in total, about $1.9M at the last price.
| Holder | Shares |
|---|---|
| Perceptive Advisors LLCDirector, 10% owner | 329,756329,756 held indirectly |
| Litton Mark JamesPRESIDENT and CEO, Director | 57,926 |
| Church KevinCHIEF SCIENTIFIC OFFICER | 25,178 |
| Worthington MarkGENERAL COUNSEL and CCO | 18,376 |
| San Martin JavierCHIEF MEDICAL OFFICER | 15,887 |
| Renninger RobertCHIEF FINANCIAL OFFICER | 15,851 |
Questions about LONA
What does LeonaBio, Inc. do?
LeonaBio, Inc. is a company in the Health care sector, listed on NASDAQ as LONA. Its shares trade on NASDAQ under the ticker LONA.
What is LeonaBio, Inc.'s net worth?
LeonaBio, Inc. has a market value (market cap) of $37.9M at the latest share price, and shareholders' equity of $33.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is LeonaBio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $141.5M.
When did LeonaBio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 22, 2026.
When is LeonaBio, Inc.'s next earnings report?
LeonaBio, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare LONA with
Follow LONA
Get an email when LeonaBio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values LeonaBio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.